“Twenty-four months efficacy and safety of LB03002, a new sustained release formulation of rhGH, in children with GHD: Extension of a phase III randomised multicentre study” are presented at the Growth Hormone and IGF-1 Research Society in Munich, Germany.

Biopartners GmbH and LG Life Sciences Ltd present positive results from their phase III paediatric trial “Twenty-four months efficacy and safety of LB03002, a new sustained release formulation of rhGH, in children with GHD: Extension of a phase III randomised multicentre study” at the Growth Hormone and IGF-1 Research Society in Munich, Germany.

Please click here to read more